Emerging roles and therapeutic implications of HDAC2 and IL-17A in steroid-resistant asthma  

作　　者：Lihuan Ouyang Guomei Su Jingyun Quan Zhilin Xiong Tianwen Lai 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Affiliated Hospital of Guangdong Medical University,Zhanjiang,Guangdong 524001,China

出　　处：《Chinese Medical Journal Pulmonary and Critical Care Medicine》2023年第2期108-112,共5页呼吸与危重症医学（英文）

基　　金：This work was supported by the Guangdong Basic and Applied Ba-sic Research Foundation(No.2020B1515020004);the National Natural Science Foundation of China(No.81873404);Project of Young Inno-vative Talents in Colleges and Universities in Guangdong Province(No.2018KQNCX095);Affiliated Hospital of Guangdong Medical University Clinical Research Program(Nos.LCYJ2018C001,LCYJ2019B011).

摘　　要：Steroid resistance represents a major clinical problem in the treatment of severe asthma,and therefore a better understanding of its pathogenesis is warranted.Recent studies indicated that histone deacetylase 2(HDAC2)and interleukin 17A(IL-17A)play important roles in severe asthma.HDAC2 activity is reduced in patients with severe asthma and smoking-induced asthma,perhaps accounting for the amplified expression of inflammatory genes,which is associated with increased acetylation of glucocorticoid receptors.Neutrophilic inflammation contributes to severe asthma and may be related to T helper(Th)17 rather than Th2 cytokines.IL-17A levels are elevated in severe asthma and correlate with the presence of neutrophils.Restoring the activity of HDAC2 or targeting the Th17 signaling pathway is a potential therapeutic approach to reverse steroid insensitivity.

关 键 词：Severe asthma Neutrophilic inflammation Histone deacetylase 2(HDAC2) Interleukin 17A(IL-17A) 

分 类 号：R562.25[医药卫生—呼吸系统]